Learn more

BIOGNOSTIK GES

Overview
  • Total Patents
    35
About

BIOGNOSTIK GES has a total of 35 patent applications. Its first patent ever was published in 1993. It filed its patents most often in EPO (European Patent Office), Australia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are HARTMANN GUNTHER, SAH DINAH WEN-YEE and REGADO BIOSCIENCES INC.

Patent filings per year

Chart showing BIOGNOSTIK GESs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Schlingensiepen Karl-Hermann 33
#2 Brysch Wolfgang 31
#3 Schlingensiepen Reimar 26
#4 Bogdahn Ulrich 11
#5 Schlingensiepen Georg-F 7
#6 Schlingensiepen Georg-Ferdinan 6
#7 Apfel Rainer 3
#8 Jachimczak Piotr 3
#9 Schlingensiepen Georg Ferdinan 2
#10 Schlingensiepen Karl-Hermann D 2

Latest patents

Publication Filing date Title
AU4650101A A method for reversing the immunosuppressive effects of the melanoma inhibitory activity "mia"
AU6010901A Mixture comprising an inhibitor or suppressor of a gene and molecule binding to an expression product of that gene
CA2334960A1 Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases
EP0856579A1 An antisense oligonucleotide preparation method
WO9517507A1 ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB PLAYS A ROLE
WO9502051A2 A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
EP1160319A2 Antisense-oligonucleotides for the treatment of immunosuppressive effects of transforming growth factor-beta (TGF-beta)
WO9425588A2 ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β)
AU5698094A Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role